药学学报, 2014, 49(8): 1097-1104
引用本文:
谭善伦, 张大志, 姜远英. 具有协同抗耐药真菌活性的天然小分子化合物研究进展[J]. 药学学报, 2014, 49(8): 1097-1104.
TAN Shan-lun, ZHANG Da-zhi, JIANG Yuan-ying. Research progress of the natural small molecular products synergistically with antifungal agents to inhibit drug-resistant fungi[J]. Acta Pharmaceutica Sinica, 2014, 49(8): 1097-1104.

具有协同抗耐药真菌活性的天然小分子化合物研究进展
谭善伦1,2, 张大志1, 姜远英1
1. 中国人民解放军第二军医大学药学院, 上海 200433;
2. 福建中医药大学药学院, 福建 福州 350112
摘要:
近几十年来,一方面深部真菌感染发生率呈显著上升趋势,另一方面真菌耐药性包括天然耐药和获得性耐药成为侵袭性真菌感染治疗失败的主要原因之一。现有抗真菌药物品种数量有限且联合应用协同作用不明显,寻找新的小分子化合物作为已有抗真菌药物的增效剂来发挥协同作用,可成为治疗侵袭性真菌感染的新策略。本文结合本课题组的研究工作及国内外报道的具有协同抗耐药真菌活性的天然小分子化合物的研究工作进行综述,对它们的来源、结构、药理活性和作用机制进行分析,以寻找其中的共性规律,为抗耐药真菌的创新药物研发提供理论基础。
关键词:    协同      抗真菌      耐药性      天然小分子化合物      构效关系     
Research progress of the natural small molecular products synergistically with antifungal agents to inhibit drug-resistant fungi
TAN Shan-lun1,2, ZHANG Da-zhi1, JIANG Yuan-ying1
1. School of Pharmacy, The Second Military Medical University, Shanghai 200433, China;
2. School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350112, China
Abstract:
The incidence of systemic fungal infections have increased dramatically, moreover, drug resistance including either primary (intrinsic) or secondary (acquired) resistance, becomes one of the main reasons accounting for the failure of treating invasive fungal infections in the past decades. Nowadays, clinically available anti-fungal drugs are limited and their combination in antifungal therapy was not effective. It is expected to be a new strategy to synergistically sensitize antifungal drugs against drug-resistant fungi by using new small mole-cules. Based on the study in our research group and the reported work of others, we reviewed the research of the natural products which have synergistic effect with the antifungal agents against drug-resistant fungi. This review focused on the resource, structure, pharmacological activity, and action mechanism of the compounds, as well as somewhat in common, and would provide theoretical base for seeking new drug against drug-resistance fungi.
Key words:    synergism    antifungal    drug resistance    natural small molecular product    structure-activity relationship   
收稿日期: 2014-01-23
基金项目: 国家自然科学基金资助项目(21072226,21272270).
通讯作者: 张大志 Tel:86-21-81871226,E-mail:zdzhang_yjhx@smmu.edu.cn;姜远英 86-21-81871357,Fax:86-21-81871226,13761571578@163.com
Email: zdzhang_yjhx@smmu.edu.cn;13761571578@163.com
相关功能
PDF(344KB) Free
打印本文
0
作者相关文章
谭善伦  在本刊中的所有文章
张大志  在本刊中的所有文章
姜远英  在本刊中的所有文章

参考文献:
[1] Sifuentes-Osornio J, Corzo-León DE, Ponce-de-Lon LA. Epidemiology of invasive fungal infections in Latin America [J]. Curr Fungal Infect Rep, 2012, 6: 23-34.
[2] Min Z, Curtis JR, Baddley JW. Epidemiologic research of invasive fungal infections using large healthcare databases [J]. Curr Fungal Infect Rep, 2013, 7: 320-325
[3] Alangaden GJ. Nosocomial fungal infections: epidemiology, infection control, and prevention [J]. Infect Dis Clin North Am, 2011, 25: 201-225.
[4] Martín Peña A, Aguilar-Guisado M, Cisneros JM. Does the current treatment of invasive fungal infection need to be reviewed? [J]. Enferm Infecc Microbiol Clin, 2013, doi: 10.1016/j.eimc.2013.02.008.
[5] Pfaller M, Neofytos D, Diekema D, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008 [J]. Diagn Micr Infec Dis, 2012, 74: 323-331.
[6] Kashyap B, Das S, Kaur IR, et al. Fungal profile of clinical specimens from a tertiary care hospital [J]. Asian Pacific J Trop Biomed, 2012, 2: S401-S405.
[7] Groll AH, Tragiannidis A. Recent advances in antifungal prevention and treatment [J]. Semin Hematol, 2009, 46: 212-229.
[8] Butts A, Krysan DJ, Goldman WE. Antifungal drug discovery: something old and something new [J]. PLoS Pathogens, 2012, 8: e1002870.
[9] McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections [J]. Drugs, 2005, 65: 2049-2068.
[10] Espinel-Ingroff A, Pfaller M, Cantón E, et al. Emerging resistance to azoles and echinocandins: clinical relevance and laboratory detection [J]. Curr Fungal Infect Rep, 2010, 4: 186-195
[11] Quan H, Cao YY, Xu Z. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole [J]. Antimicrob Agents Chemother, 2006, 50: 1096-1099.
[12] Xu Y, Wang Y, Yan L, et al. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: endogenous ROS augmentation [J]. J Proteome Res, 2009, 8: 5296-5304.
[13] Liang XY, Guo N, Wang LS, et al. Study on in vitro antifungal activity of dictiamnine against Candida albicans [J]. Chin Agric Sci Bull (中国农学通报), 2009, 25: 21-24.
[14] Guo N. Study on the in Vitro Antifungal Activities and Actions Mechanism of Furoquinoline Alkaloid Dictamnine (呋喃喹啉类生物碱白鲜碱体外抗真菌活性及作用机制研究) [D]. Changchun: Jilin University, 2009.
[15] Debray M, Plat M, Le Men J. Alkaloids of African Menis-permaceae, Epinetrum cordifolium and Epinetrum mangenotii: isolation of cycleanine, norcycleanine and isochondrodendrine [J]. Ann Pharm Fr, 1966, 24: 551-558.
[16] Zhang HY, Li ZM, Zhang S, et al. Chemical constituents of cultivated fibraurea recisa pierre [J]. Med Pharm Yunnan (云南中医学院学报), 2008, 31: 28-31.
[17] Xu X, Sun CR, Dai XJ, et al. LC/MS guided isolation of alkaloids from lotus leaves by pH-zone-refining counter-current chromatography [J]. Molecules, 2011, 16: 2551-2560.
[18] Phillipson JD, Thomas OO, Gray AI, et al. Alkaloids from Papaver armeniacum, P. fuga and P. tauricola [J]. Planta Med, 1981, 41: 105-118.
[19] Agnihotri VK, ElSohly HN, Khan SI, et al. Constituents of Nelumbo nucifera leaves and their antimalarial and antifungal activity [J]. Phytochem Lett, 2008, 1: 89-93.
[20] Wang HM. In Vitro Anti-deep Fungal Activity Study of Chemical Constituents of Fibraurea Recisa Pierre (黄藤化学 成分体外抗深部真菌活性研究) [D]. Kunming: Kunming Medical University, 2008.
[21] Xu GL, Rao GX, Wang HM, et al. Use of aporphine alkaloid and derivative in preparing anti-figus medicine: CN, 200810233655.8 [P]. 2008-11-28.
[22] Li FX, Zhang H, Shan KR. In vitro study on the synergistic effect and mechanism of tetrandrine to fluconazole hyphal form of Candida albicans [J]. Chin J Zoonoses (中国人兽共患病学报), 2009, 25: 13-16.
[23] Li FX, Zhang H. In vitro study of the synergistic effect of tetrandrine and fluconazole against Candida albicans [J]. Chin J Dermatol (中华皮肤科杂志), 2006, 39: 454-456.
[24] Wang KL, Zhang H, Jiang HH, et al. In vitro study on tetrandrine as a synergist to fluconazole in murine model of vaginal candidiasis [J]. Chin J Zoonoses (中国人兽共患病学报), 2007, 23: 474-478.
[25] Wu S. Tetrandrine Synergy with Fluconazole Against Can-dida Comparative Proteomics (汉防己甲素与氟康唑协同抗白念珠菌作用的比较蛋白组学研究) [D]. Zhongshan: Zhongshan University, 2010.
[26] Tao R, Pan Y. Research procress on nonphenolic alkaloids from Nelumbo nucifera [J]. Res Pract Chin Med (现代中药研究与实践), 2008, 22: 63-64.
[27] Zhang H, Gao AL, Li F, et al. Mechanism of action of tetrandrine, a natural inhibitor of Candida albicans drug efflux pumps [J]. Pharm Soc Japan, 2009, 129: 623-630.
[28] Zhang X, Guo H, Gao L, et al. Molecular mechanisms underlying the tetrandrine-mediated reversal of the fluconazole resistance of Candida albicans [J]. Pharm Biol, 2013, 51: 749-752.
[29] Jin J, Guo N, Zhang J, et al. The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans [J]. Lett Appl Microbiol, 2010, 51: 351-357.
[30] Jin J. Basic Study on the Antifungal Activity and Action Mechanism of Honokiol (中药和厚朴酚抗真菌活性及其作用机制的初步研究) [D]. Changchun: Jilin University, 2011.
[31] Liu W, Liu YL, Cao YB, et al. Use of forsythiaside as synergist of antifungal agents: CN, 201010157463.0 [P]. 2010-04-27.
[32] Ali I, Sharma P, Suri KA, et al. In vitro antifungal activities of amphotericin B in combination with acteoside, a phenylethanoid glycoside from Colebrookea oppositifolia [J]. J Med Microbiol, 2011, 60: 1326-1336.
[33] Garcia-Gomes AS, Curvelo JA, Soares RM, et al. Curcumin acts synergistically with fluconazole to sensitize a clinical isolate of Candida albicans showing a MDR phenotype [J]. Med Mycol, 2012, 50: 26-32.
[34] Sharma M, Manoharlal R, Negi AS, et al. Synergistic anticandidal activity of pure polphenol curcumin I in combination with azoles and polyenes generates reactive oxygen species leading to apoptosis [J]. FEMS Yeast Res, 2010, 10: 570-578.
[35] Khan MSA, Malik A, Ahmad I. Anti-candidal activity of essential oils alone and in combination with amphotericin B or fluconazole against multi-drug resistant isolates of Candida albicans [J]. Med Mycol, 2011, 50: 33-42.
[36] Faria NCG, Kim JH, Goncalves LAP, et al. Enhanced activity of antifungal drugs using natural phenolics against yeast strains of Candida and Cryptococcus [J]. Lett Appl Microbiol, 2011, 52: 506-513.
[37] Fujita K, Fujita T, Kubo I. Anethole, a potential antimicro-bial synergist, converts a fungistatic dodecanol to a fungicidal agent [J]. Phytother Res, 2007, 21: 47-51.
[38] Cao YY, Zhu ZY, Zheng ZY, et al. Application of kaempferol as synergist of anti-fungal medicaments: CN, 201110087126.3 [P]. 2011-10-19.
[39] Huang S, Cao YY, Dai BD, et al. In Vitro synergism of fluconazole and baicalein against clinical isolates of Candida albicans resistant to fluconazole [J]. Biol Pharm Bull, 2008, 31: 2234-2236.
[40] Cao YY, Dai BD, Wang Y, et al. In vitro activity of baicalein against Candida albicans biofilms [J]. Int J Antimicrob Agents, 2008, 32: 73-77.
[41] Dai BD, Cao YY, Huang S, et al. Baicalein induces programmed cell death in Candida albicans [J]. J Microbiol Biotechnol, 2009, 19: 803-809.
[42] Cao YY, Zheng ZY, Zhu ZY, et al. Application of mangiferin as synergist of antifungal agents: CN, 201110087412.X [P]. 2011-04-08.
[43] Rukayadi Y, Lee K, Lee MS, et al. Synergistic anticandidal activity of xanthorrhizol in combination with ketoconazole or amphotericin B [J]. FEMS Yeast Res, 2009, 9: 1302-1311.
[44] Guo N, Ling G, Liang X, et al. In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans [J]. Mycoses, 2011, 54: e400.
[45] Gong YJ. Antifugal Traditional Chinese Medicines Screening and Study on the Mechanism of Action of Anti-fungal Compound From Cortex Pseudolaricis (抗真菌中药筛选及土槿皮抗真菌活性成分作用机制研究) [D]. Changchun: Jilin University, 2001.
[46] Sun L, Sun S, Cheng A, et al. In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans [J]. Antimicrob Agent Chemther, 2009, 53: 1586-1591.
[47] Chang WQ. The Anfungal Mechanism of Retigeric Acid B and the Construction of Molecule Tool in the Canidia albicans. (Retigeric acid B的抗真菌机制及白念珠菌中分子工具的构建) [D]. Ji’nan: Shandong University, 2013.
[48] Xu Y, Pang GR, Lü XF, et al. The effect of propyl gallate on the activity of various antifungal drugs against filamentous fungi in vitro [J]. Chin J Ophthalmol (中华眼科杂志), 2006, 42: 309-312.
[49] D'Auria FD, Tecca M, Strippoli R, et al. In vitro activity of propyl gallate-azole drug combination against fluconazole- and itraconazole-resistant Candida albicans strains [J]. Lett Appl Microbiol, 2001, 32: 220-223.
[50] Endo EH, Cortez DA, Ueda-Nakamura T, et al. Potent antifungal activity of extracts and pure compound isolated from pomegranate peels and synergism with fluconazole against Candida albicans [J]. Res Microbiol, 2010, 161: 534-540.
[51] An MM. Allicin Enhances the Effect of Amphotericin B Against Candida Albicans (Allicin协同两性霉素B抗白念珠菌机制研究) [D]. Shanghai: The Second Military Medical University, 2011.
[52] Ogita A, Fujita K, Taniguchi M, et al. Dependence of synergistic fungicidal activity of Cu2+ and allicin, an allyl sulfur compound from garlic, on selective accumulation of the ion in the plasmamembrane fraction via allicin-mediated phospholipid peroxidation [J]. Planta Med, 2006, 72: 875-880.
[53] Guo N, Wu XP, Yu L, et al. In vitro and in vivo interactions between fluconazole and allicin against clinical isolates of fluconazole-resistant Candida albicans determined by alternative methods [J]. FEMS Immunol Med Microbiol, 2010, 58: 193-201.
[54] Khodavandi A, Alizadeh F, Aala F, et al. In vitro investiga-tion of antifungal activity of allicin alone and in combination with azoles against Candida species [J]. Mycopathologia, 2010, 169: 287-295.
[55] Zhu ZY, Cao YY, Zheng ZY, et al. Use of shikonin as antifungal medicine synergist: CN, 201110078915.0 [P]. 2011-09-28.
[56] Guo XL, Leng P, Yang Y, et al. Plagiochin E, a botanic-derived phenolic compound, reverses fungal resistance to fluconazole relating to the efflux pump [J]. J Appl Microbiol, 2008, 104: 831-838.
[57] Liu YL, Liu W, Cao YB, et al. Application of theaflavin as synergist of antifungal medicine: CN, 201010157469.8 [P]. 2010-04-27.
[58] Zhao ZM, Wan JH, Chen BY. Susceptibility of 35 Candida strains to fluconazole and in vitro effects in coordination of the fluconazole and cyclosporine [J]. Chin J Clin Pharmacol (中国临床药理学杂志), 2006, 22: 273-275.
[59] Maesaki S, Marichal P, Hossain MA, et al. Synergic effects of tacrolimus and azole antifungal agents against az-ole-resistant Candida albican strains [J]. Antimicrob Chemother, 1998, 42: 745-753.
[60] Uppuluri P, Nett J, Heitman J, et al. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms [J]. Antimicrob Agents Chemother, 2008, 52: 1127-1132.
[61] Cao YY, Shang QH, Zhu ZY, et al. Application of sodium houttuyfonate use as antifungal synergist CN, 201010285768.X [P]. 2011-02-02.
[62] Chandra J, Mukherjee PK, Leidich SD, et al. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro [J]. J Dent Res, 2001, 80: 903-908.
[63] Ramage G, VandeWalle K, Wickes BL, et al. Characteristic-s of biofilm formation by Candida albicans [J]. Rev Iberoam Micol, 2001, 18: 163-170.
[64] Liu H, Wang L, Li Y, et al. Structural optimization of ber-berine as a synergist to restore antifungal activity of fluconazole against drug-resistant Candida albicans [J]. ChemMed-Chem, 2014, 9: 207-216.
相关文献:
1.时 园 周成合 周向东 耿蓉霞 吉庆刚.香豆素苯并三唑的合成、抗微生物活性及其与氯霉素和氟康唑协同作用研究[J]. 药学学报, 2011,46(7): 798-810
2.王胜正 盛春泉 张万年.新型抗真菌先导化合物的研究进展[J]. 药学学报, 2010,45(8): 966-975
3.邵律成;盛春泉;张万年.新结构类型抗真菌先导化合物的研究进展[J]. 药学学报, 2007,42(11): 1129-1136
4.盛春泉;朱杰;张万年;宋云龙;张珉;季海涛;余建鑫;姚建忠;杨松;缪震元.新型三唑类化合物的合成及抗真菌活性[J]. 药学学报, 2004,39(12): 984-989
5.张大志;周廷森;吴义杰;刘超美;麻铭川;冯向庭.1-(1H-1,2,4-三唑-1-基)-2-(2,4-二氟苯基)-3-取代-2-丙醇的合成及抗真菌活性研究[J]. 药学学报, 1997,32(12): 943-949